These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

72 related articles for article (PubMed ID: 8851384)

  • 41. Doripenem versus Pseudomonas aeruginosa in vitro: activity against characterized isolates, mutants, and transconjugants and resistance selection potential.
    Mushtaq S; Ge Y; Livermore DM
    Antimicrob Agents Chemother; 2004 Aug; 48(8):3086-92. PubMed ID: 15273124
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Comparison of antibacterial activities of meropenem and six other antimicrobials against Pseudomonas aeruginosa isolates from North American studies and clinical trials.
    Iaconis JP; Pitkin DH; Sheikh W; Nadler HL
    Clin Infect Dis; 1997 Feb; 24 Suppl 2():S191-6. PubMed ID: 9126693
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Multiple antibiotic resistance (mar) locus protects Escherichia coli from rapid cell killing by fluoroquinolones.
    Goldman JD; White DG; Levy SB
    Antimicrob Agents Chemother; 1996 May; 40(5):1266-9. PubMed ID: 8723480
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Emergence of multidrug-resistant mutants is increased under antibiotic selective pressure in Pseudomonas aeruginosa.
    Alonso A; Campanario E; Martínez JL
    Microbiology (Reading); 1999 Oct; 145 ( Pt 10)():2857-62. PubMed ID: 10537207
    [TBL] [Abstract][Full Text] [Related]  

  • 45. gyrA mutations in high-level fluoroquinolone-resistant clinical isolates of Escherichia coli.
    Conrad S; Oethinger M; Kaifel K; Klotz G; Marre R; Kern WV
    J Antimicrob Chemother; 1996 Sep; 38(3):443-55. PubMed ID: 8889719
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Antimicrobial resistance and genetic characterization of fluoroquinolone resistance of Pseudomonas aeruginosa isolated from canine infections.
    Rubin J; Walker RD; Blickenstaff K; Bodeis-Jones S; Zhao S
    Vet Microbiol; 2008 Sep; 131(1-2):164-72. PubMed ID: 18395369
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Bacteriostatic and bactericidal activities of eight fluoroquinolones against MexAB-OprM-overproducing clinical strains of Pseudomonas aeruginosa.
    Dupont P; Hocquet D; Jeannot K; Chavanet P; Plésiat P
    J Antimicrob Chemother; 2005 Apr; 55(4):518-22. PubMed ID: 15722391
    [TBL] [Abstract][Full Text] [Related]  

  • 48. In vitro efficacy of levofloxacin alone or in combination tested against multi-resistant Pseudomonas aeruginosa strains.
    Flynn CM; Johnson DM; Jones RN
    J Chemother; 1996 Dec; 8(6):411-5. PubMed ID: 8981179
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Antimicrobial Effects of β-Lactams on Imipenem-Resistant Ceftazidime-Susceptible Pseudomonas aeruginosa.
    Wi YM; Choi JY; Lee JY; Kang CI; Chung DR; Peck KR; Song JH; Ko KS
    Antimicrob Agents Chemother; 2017 Jun; 61(6):. PubMed ID: 28373200
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Single- and multi-step resistance selection study of gemifloxacin compared with trovafloxacin, ciprofloxacin, gatifloxacin and moxifloxacin in Streptococcus pneumoniae.
    Nagai K; Davies TA; Dewasse BE; Jacobs MR; Appelbaum PC
    J Antimicrob Chemother; 2001 Sep; 48(3):365-74. PubMed ID: 11533001
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Fluoroquinolone-resistant Brucella melitensis mutants obtained in vitro.
    Lázaro FG; Rodríguez-Tarazona RE; García-Rodríguez JA; Muñoz-Bellido JL
    Int J Antimicrob Agents; 2009 Sep; 34(3):252-4. PubMed ID: 19243922
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Fluoroquinolone supersusceptibility mediated by outer membrane protein OprH overexpression in Pseudomonas aeruginosa: evidence for involvement of a nonporin pathway.
    Young M; Hancock RE
    Antimicrob Agents Chemother; 1992 Nov; 36(11):2365-9. PubMed ID: 1336943
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Relationships among ciprofloxacin, gatifloxacin, levofloxacin, and norfloxacin MICs for fluoroquinolone-resistant Escherichia coli clinical isolates.
    Becnel Boyd L; Maynard MJ; Morgan-Linnell SK; Horton LB; Sucgang R; Hamill RJ; Jimenez JR; Versalovic J; Steffen D; Zechiedrich L
    Antimicrob Agents Chemother; 2009 Jan; 53(1):229-34. PubMed ID: 18838594
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [A study on the mechanism of the resistance of Shigellae to fluoroquinolones].
    Ding J; Ma Y; Gong Z; Chen Y
    Zhonghua Nei Ke Za Zhi; 1999 Aug; 38(8):550-3. PubMed ID: 11798696
    [TBL] [Abstract][Full Text] [Related]  

  • 55. gyrA and parC mutations in quinolone-resistant clinical isolates of Pseudomonas aeruginosa from Nini Hospital in north Lebanon.
    Salma R; Dabboussi F; Kassaa I; Khudary R; Hamze M
    J Infect Chemother; 2013 Feb; 19(1):77-81. PubMed ID: 22821356
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Antibacterial activity of a new tetracyclic quinolone, No. 5290, against norfloxacin- and ciprofloxacin-resistant strains of Staphylococcus aureus.
    Kotera Y; Inoue Y; Ohashi M; Ito K; Tsukamoto G
    Chem Pharm Bull (Tokyo); 1991 Oct; 39(10):2644-6. PubMed ID: 1666861
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Mechanisms accounting for fluoroquinolone resistance in Escherichia coli clinical isolates.
    Morgan-Linnell SK; Becnel Boyd L; Steffen D; Zechiedrich L
    Antimicrob Agents Chemother; 2009 Jan; 53(1):235-41. PubMed ID: 18838592
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Patterns of quinolone susceptibility in Campylobacter jejuni associated with different gyrA mutations.
    McIver C; Hogan T; White P; Tapsall J
    Pathology; 2004 Apr; 36(2):166-9. PubMed ID: 15203753
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Efflux pump contribution to multidrug resistance in clinical isolates of Pseudomonas aeruginosa.
    Kiser TH; Obritsch MD; Jung R; MacLaren R; Fish DN
    Pharmacotherapy; 2010 Jul; 30(7):632-8. PubMed ID: 20575627
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [A study on the resistance of Staphylococcus aureus and the mechanisms of its resistance to fluoroquinolone].
    Lei Y; Gui X; Feng G
    Zhonghua Nei Ke Za Zhi; 2001 Mar; 40(3):176-9. PubMed ID: 11798575
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.